- Meta-analysis of 9 randomized trials suggests that black vs white men with metastatic castration-resistant prostate cancer (mCRPC) show 19% lower risk for mortality.
Why this matters
- Limited data are available on racial disparities in men with advanced disease.
- Meta-analysis of individual participant data from 9 randomized controlled trials (RCTs; including 8820 men with mCRPC, treated with docetaxel + prednisone alone or in combination with other therapies).
- Funding: United States Army Medical Research.
- Median follow-up time was 31 months.
- Mortality rate was 68% vs 62% in black and white men, respectively.
- 85% of patients were white and 6% were black.
- Black patients were younger, had worse performance status, higher testosterone and PSA, and lower hemoglobin vs white patients.
- Median OS was 21.0 months in black men and 21.2 months in white men.
- Black men showed significantly lower risk for death:
- Overall (pooled HR, 0.81; P<.001>
- In the National Clinical Trials Network (NCTN) trials: pooled HR, 0.76 (95% CI, 0.66-0.88);
- In patients treated with docetaxel + prednisone: pooled HR, 0.79 (95% CI, 0.67-0.93);
- Patients assigned to docetaxel + prednisone in NCTN trials: pooled HR, 0.71 (95% CI, 0.58-0.87).
- Findings may not be generalizable.